ストックスクリーナーアプリを入手
12.68
2.46%
-0.32
Rapport Therapeutics Inc (RAPP) 最新ニュース
Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 8.5%Here's What Happened - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat
How To Trade (RAPP) - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 5.6%What's Next? - MarketBeat
Jennison Associates LLC Acquires Shares of 62,287 Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Short Interest Down 15.3% in January - MarketBeat
JPMorgan Chase & Co. Purchases Shares of 4,033 Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Trading Up 4.6%Here's What Happened - MarketBeat
J&J-backed Rapport Therapeutics files for $100M IPO - MSN
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
(RAPP) Proactive Strategies - Stock Traders Daily
Rapport Therapeutics (RAPP) Projected to Post Quarterly Earnings on Thursday - Defense World
‘A really rational IPO environment’: What does it takes for a biotech to go public now? - Fierce Biotech
Barclays PLC Increases Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Reaches New 12-Month LowWhat's Next? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownWhat's Next? - MarketBeat
Rapport Therapeutics Announces Positive Results from PET and MAD-2 Trials for RAP-219On January 9, 2025, Rapport Therapeutics, Inc. (NASDAQ: RAPP) disclosed the outcomes from its positron emission tomography (PET) trial and the second multiple as - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%What's Next? - MarketBeat
(RAPP) Technical Data - Stock Traders Daily
Rapport Therapeutics announces new Phase 1 data for RAP-219 - Yahoo Finance
CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times
CORRECTION -- Rapport Therapeutics Announces New Phase 1 - GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - The Manila Times
Rapport Therapeutics Announces New Phase 1 Data, Further - GlobeNewswire
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders - GlobeNewswire Inc.
Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's ... - The Bakersfield Californian
Rapport Therapeutics (NASDAQ:RAPP) Sets New 52-Week LowHere's What Happened - MarketBeat
Geode Capital Management LLC Makes New $4.13 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Geode Capital Management LLC Purchases New Shares in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Barclays PLC Has $264,000 Stock Holdings in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
State Street Corp Invests $1.19 Million in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
58,046 Shares in Rapport Therapeutics (NASDAQ:RAPP) Purchased by State Street Corp - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4%Here's Why - MarketBeat
Learn to Evaluate (RAPP) using the Charts - Stock Traders Daily
TARPγ8 negative allosteric modulators as new approach for epilepsy - BioWorld Online
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13 - Business Wire
Shareholder Alert: Ademi LLP investigates whether Nordstrom, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
When (RAPP) Moves Investors should Listen - Stock Traders Daily
1,684 Shares in Rapport Therapeutics (NASDAQ:RAPP) Bought by BNP Paribas Financial Markets - Defense World
LTRPA, LTRPB Investors Have the Opportunity to Join Investigation of Liberty TripAdvisor Holdings, Inc. with the Schall Law Firm - Business Wire
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025 - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.6%Should You Sell? - MarketBeat
The Manitowoc Company reaches agreement to settle U.S. EPA matter regarding its emissions certification and compliance process - Business Wire
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7%Should You Buy? - MarketBeat
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):